Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 9/20 | 0.75 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.75 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,S)-Fidarestat SCHEMBL1219758 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL2855039 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL48828 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| Fidarestat SCHEMBL48827 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL29941924 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| Fidarestat SCHEMBL29546775 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL14197081 | 0.86 | AKR1B1 (0.75) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL25063565 | 0.83 | AKR1B1 (0.71) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL25892734 | 0.81 | AKR1B1 (0.63) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL10674222 | 0.81 | AKR1B1 (0.71) | AKR1B1AKR1B10AKR1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1B1 9/4885AKR1B10 26/4885AKR1A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.